Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(17%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
3
50%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(3)

Detailed Status

unknown3
Active, not recruiting1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
N/A1 (16.7%)

Trials by Status

active_not_recruiting117%
completed117%
terminated117%
unknown350%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_2

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

NCT04418154
unknownphase_1

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

NCT04460066
unknownphase_1

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

NCT04603846
completedphase_2

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

NCT02229058
terminatednot_applicable

Endoscopic Abraxane Injection Into Pancreatic Cysts

NCT01698710
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04418154Phase 2

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Active Not Recruiting
NCT04460066Phase 1

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Unknown
NCT04603846Phase 1

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Unknown
NCT02229058Phase 2

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Completed
NCT01698710Not Applicable

Endoscopic Abraxane Injection Into Pancreatic Cysts

Terminated
NCT02229045Phase 2

Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6